About the Event
AyuVis is developing a new class of drugs with broad-based applications that include the treatment of some of today’s most common and debilitating diseases. The initial list includes Sepsis, Renal Disease, Acute Respiratory Distress Syndrome (ARDS), as well as other respiratory, ocular, and dermatology applications. All together, the global market opportunity for these indications exceeds $100B annually.
AyuVis compounds are unique thanks to their triple action immunomodulation, anti-inflammatory, and anti-microbial activities. The flexibility of this platform creates the potential to treat many more indications than a single-target compound.
Please join our webinar with AyuVis founder and CEO, Dr. Suchi Acharya and her team, who will talk about the expedited approval process for AVR-48 which has received an Orphan Drug Designation from the FDA and the other opportunities for the compound which have the potential to exceed $100B annually.